# Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors

> **NCT01239134** · PHASE1 · COMPLETED · sponsor: **Leap Therapeutics, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Unresectable Stage III or Stage IV Malignant Melanoma or Other Solid Tumor Malignancies

## Interventions

- **BIOLOGICAL:** TRX518

## Key facts

- **NCT ID:** NCT01239134
- **Lead sponsor:** Leap Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-08-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01239134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01239134, "Trial of TRX518 (Anti-GITR mAb) in Stage III or IV Malignant Melanoma or Other Solid Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01239134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*